Worldwide in 2024, approximately one in eight new cancer cases—totaling 2.3 million diagnoses—stemmed from bacterial, viral, or parasitic infections, according to an international analysis published in The Lancet Oncology by researchers at the International Agency for Research on Cancer.
When the International Agency for Research on Cancer released its updated assessment, the findings reframed a familiar landscape. While public health messaging routinely directs attention toward lifestyle factors like smoking, alcohol consumption, and inherited genetics, microbial drivers account for roughly 12 percent of the global cancer burden according to findings published in The Lancet Oncology.
Five Microbial Pathogens Driving Global Cases
The research examined twelve pathogens classified as human carcinogens, but five specific agents concentrated the vast majority of infektionsbedingte tumors worldwide in 2024. Helicobacter pylori led the global statistics, linked to approximately 760,000 cases, predominantly stomach cancers. Close behind, human papillomaviruses accounted for roughly 750,000 diagnoses, driving more than 90 percent of cervical cancer cases alongside tumors of the anus, penis, and oropharynx.
Rounding out the primary group, hepatitis B contributed 360,000 cases primarily affecting the liver, while the Epstein-Barr virus accounted for 260,000 diagnoses spanning nasopharyngeal carcinomas, specific lymphomas, and gastric cancers. Hepatitis C drove an additional 160,000 liver-related tumor cases as detailed in international health data.
Low and Middle Income Countries Bear Most Infection Linked Cancers
The burden of infection-linked malignancies is distributed unevenly across the globe. Low- and middle-income countries account for 77 percent of these cancer cases. East Asia absorbs 42 percent of the global total, driven heavily by regional concentrations of Helicobacter pylori and hepatitis B reported by researchers affiliated with the World Health Organization. Sub-Saharan Africa faces a distinct impact, where roughly one in four tumors connects to an infection, particularly HPV and pathogens linked with Kaposi sarcoma compounded by HIV.
Western Europe presents a different baseline. In Germany, health authorities recorded 29,000 infection-linked cancer cases in 2024, with HPV and Helicobacter pylori accounting for the substantial majority noted in public health assessments.
Ute Mons of the German Cancer Research Center noted, Not every infection with these pathogens leads to cancer.
Immunizations and Antiviral Treatments Can Reduce Cancer Incidence
Because these tumors originate from infectious agents, established medical tools can intercept the pathway before malignant changes occur. Immunizations against HPV and hepatitis B, direct-acting antiviral treatments capable of curing hepatitis C in over 95 percent of cases, and eradication regimens for Helicobacter pylori offer proven pathways to reduce incidence outlined by the International Agency for Research on Cancer.
Yet implementation remains uneven.
Infectious Agents Caused 2.3 Million Cancer Cases in 2024
The study, published on September 28, 2026, in The Lancet Oncology by researchers including Harriet Rumgay, D. Georges, Y. Huang, M. Hirabayashi, R. Shah, and C. de Martel from the International Agency for Research on Cancer, establishes that approximately 2.3 million new cancer cases in 2024 were attributable to twelve recognized infectious agents. The authors utilized population-attributable fractions based on infection prevalence among cancer cases, extracting national incidence figures from the Global Cancer Observatory’s GLOBOCAN database.
Readers can conclude from this evidence that infection-linked cancers represent an estimated 12 percent of the global cancer burden, with specific pathogens dominating the caseload in distinct geographic regions and income brackets. However, readers cannot conclude that every infection leads to malignancy, as the vast majority of infected individuals do not develop tumors, and other interacting factors such as host genetics, immune status, and lifestyle contribute to disease progression.
For guidance regarding personal health risks, screening schedules, or preventive measures such as vaccinations and targeted diagnostics, individuals should consult qualified medical professionals or healthcare providers rather than relying solely on epidemiological statistics.